New diabetic agents providing a glucose feast for urinary yeast – what to do?

This article discusses the potential risks and complications associated with the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i), a type of medication used to treat type 2 diabetes. The article highlights the increased risk of urinary yeast infections, including Candida glabrata, in patients taking SGLT2i. It also mentions the association between SGLT2i use and serious urinary tract infections, genital mycotic infections, and Fournier's gangrene. The article emphasizes the importance of clinician awareness and appropriate management of these complications, including the use of antifungal therapy and discontinuation of SGLT2i in severe cases. [Extracted from the article]